Evidence map›Paper›PMID 36803941›Full record

ReviewJournal of medical case reports2023

Bilateral primary angiosarcoma of the breast: a case report.

Yuka Ooe, Hirofumi Terakawa, Hiroko Kawashima, Hiroko Ikeda, Noriyuki Inaki

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Journal of medical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yuka OoeDepartment of Breast Surgery, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan. y.ooe0003@gmail.com.ORCID http://orcid.org/0000-0002-1761-6739
Hirofumi TerakawaDepartment of Breast Surgery, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan.
Hiroko KawashimaBreast Center, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan.
Hiroko IkedaDepartment of Diagnostic Pathology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan.
Noriyuki InakiDepartment of Gastrointestinal Surgery/Breast Surgery, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan.
Kanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary angiosarcoma of the breast is very rare, accounting for 0.05% of all malignant breast tumors. It has very high malignant potential and poor prognosis, though due to the rarity of the disease, there is no established treatment. We report this case along with a literature review. CASE PRESENTATION: We report the case of a 30-year-old Asian woman who was diagnosed with bilateral primary angiosarcoma of the breast while breastfeeding. After surgery, she underwent radiation therapy, chemotherapy, and hepatic arterial infusion chemotherapy for local recurrence of liver metastases, but these were ineffective, and she required several arterial embolization procedures for intratumoral bleeding and rupture of liver metastases.

conclusionsAngiosarcoma has a poor prognosis due to a high rate of local recurrence and distant metastasis. Although there is no established evidence for radiotherapy or chemotherapy, multimodality treatment may be necessary because of the high malignancy and rapid progression of the disease.

Indexed as

Breast NeoplasmsHemangiosarcomaLiver NeoplasmsAdultCombined Modality TherapyFemaleHumansAngiosarcomaArterial embolizationBreastBreastfeeding

Identifiers

PMID36803941
PMCPMC9942292
OpenAlexW4321366456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.